Are TNF inhibitors still the agent of choice for RA?

被引：0
|
作者：
Taylor, Peter C. [1 ]
机构：
[1] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskeleta, Oxford, England
来源：
NATURE REVIEWS RHEUMATOLOGY | 2023年
关键词：
RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; METHOTREXATE; COMBINATION; ADALIMUMAB;
D O I：
10.1038/s41584-023-01043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set to remain an important treatment option for the foreseeable future.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors.
    Kremer, J. M.
    Tony, H. P.
    Tak, P. P.
    Luggen, M.
    Mariette, X.
    Hessey, E.
    McCabe, D.
    Safa-Leathers, S.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S247 - S248
  • [42] Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
    Adams, Cameron
    Marker, Katie
    Krueger, Melissa
    Barcellos, Lisa
    Criswell, Lindsey A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [43] TNF-INHIBITORS AND ITS EFFECT ON DISEASE COURSE AND PREGNANCY OUTCOME IN RA AND SPA PATIENTS
    Van den Brandt, S.
    Zbinden, A. J.
    Baeten, D.
    Villiger, P. M.
    Forger, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 470 - 471
  • [44] Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
    Manders, Sofie H. M.
    van de Laar, Mart A. F. J.
    Rongen-van Dartel, Sanne A. A.
    Bos, Reinhard
    Visser, Henk
    Brus, Herman L.
    Jansen, Tim
    Vonkeman, Harald E.
    van Riel, Piet L. C. M.
    Kievit, Wietske
    RMD OPEN, 2015, 1 (01):
  • [45] Combination intensive DMARD therapy is noninferior to TNF inhibitors for reducing disability in active RA Comment
    McLeod, B. D.
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (04) : JC9 - JC9
  • [46] DISEASE ACTIVITY MEASURES AND OTHER POTENTIAL PREDICTORS OF SUCCESSFUL TNF INHIBITORS TAPERING IN RA PATIENTS
    Bogas, P.
    Plasencia, C.
    Guinazu, F.
    Novella-Navarro, M.
    Navarro-Compan, V.
    Franco Gomez, K. N.
    Monjo, I.
    Balsa, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 616 - 617
  • [47] Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
    Holstein, Katharina
    Le Quellec, Sandra
    Klamroth, Robert
    Batorova, Angelika
    Holme, Pal Andre
    Jimenez-Yuste, Victor
    Astermark, Jan
    HAEMOPHILIA, 2022, 28 (02) : 215 - 222
  • [48] PERSISTENCE TO BIOLOGICAL DMARDS TNF INHIBITORS VS BIOLOGICAL DMARDS NO TNF INHIBITORS AFTER FAILURE TO SYNTHETIC CONVENTIONAL DMARDS IN RA PATIENTS TREATED IN STANDARD CLINICAL PRACTICE
    Hernandez-Cruz, B.
    Munoz Reinoso, P.
    Garcia Hernandez, I.
    Jurado Quijano, G.
    de la Fuente Burson, L. Fernandez
    Fernandez-Maeztu Palacin, I. M.
    Reboul Fernandez, A. Fernandez
    Ruiz-Montesinos, D.
    Perez Venegas, J. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1145 - 1145
  • [49] STILL A FATEFUL CHOICE
    BAUER, E
    PUISEUX, L
    TENIEREBUCHOT, PF
    BULLETIN OF THE ATOMIC SCIENTISTS, 1976, 32 (10) : 45 - 45
  • [50] Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy
    Amstad, Andrea
    Papagiannoulis, Eleftherios
    Scherer, Almut
    Rubbert-Roth, Andrea
    Finckh, Axel
    Mueller, Ruediger
    Dudler, Jean
    Moeller, Burkhard
    Villiger, Peter M.
    Schulz, Martin M. P.
    Kyburz, Diego
    RHEUMATOLOGY, 2022, 62 (01) : 89 - 97
12345